Neuronix Ltd.


Therapeutic Area(s):
Neurology and Degenerative Diseases
Company Status:
Initial Revenues

Company at a Glance

Established in 2008, Neuronix is a privately held medical device company with headquarters in Israel, corporate offices in the US and a knowledgeable European sales team. Neuronix has developed the patented NeuroAD System, the only proven, non-pharmaceutical, non-invasive treatment for patients diagnosed with Alzheimer’s Disease (AD), which combines cognitive training and transcranial magnetic stimulation (rTMS) to increase cognitive capabilities of AD patients. The CE-marked NeuroAD System is currently available at
sites throughout Europe and Israel.

Technology & Product(s)

The NeuroAD System is the only proven, non-pharmaceutical, non-invasive treatment of Alzheimer’s Disease (AD). The combination of TMS and cognitive training results in rapid, sustained improvement in cognitive function and increased daily living function for patients diagnosed with AD. The NeuroAD System has been tested across multiple worldwide clinical trials, yielding noteworthy improvement in ADAS-Cog scores with sustained results. This treatment may also be used in conjunction with existing pharmacological treatments and has minimal side effects. A multi-site clinical study has been completed in the United States for the company’s pursuit of FDA clearance. Commercially available to clinics in Europe and Israel, this innovative technology addresses the burgeoning problem of AD and provides a unique distribution opportunity worldwide.

Goals

Objectives: Worldwide market introduction.
Target businesses: Distribution partners and agents.
Target Countries: Worldwide.